Skip to main content
. 2016 Mar 22;11(5):3167–3172. doi: 10.3892/ol.2016.4364

Figure 3.

Figure 3.

(A) Cell migration assay was performed to determine cell invasion levels in ccRCC cells treated with Aza (10 nM) for 72 h. Control cells did not receive treatment. **P<0.01 vs. control. (B) Reverse transcription-polymerase chain reaction was performed to determine the relative expression of miR-200c in Aza-treated ccRCC cells transfected with miR-200c inhibitor. Aza-treated ccRCC cells served as a control. **P<0.01 vs. Aza. (C) Cell migration assay was performed to determine cell invasion levels in Aza-treated ccRCC cells transfected with miR-200c inhibitor. Aza-treated ccRCC cells served as a control. **P<0.01 vs. Aza. ccRCC, clear cell renal cell carcinoma; Aza, 5-Aza-2′-deoxycytidine; miR, microRNA.